Is Chemomab Therapeutics Ltd DRC (CMMB) overvalued? · $22.2M cap
Chemomab Therapeutics Ltd DRC (CMMB) is a biotechnology company listed on US.
This page asks whether Chemomab Therapeutics Ltd DRC (CMMB) looks expensive on cached numbers — not a short thesis.
No cached income statement for CMMB, so there is no earnings base to call rich or cheap.
CMMB currently screens at market cap $22.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CMMB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CMMB stock page for the full model, not this heading.
Not investment advice.